ARTICLE | Company News
BTG, Senexis AD deal
February 3, 2006 3:14 AM UTC
BTG (LSE:BGC) granted Senexis ( Cambridge, U.K.) an exclusive license to undisclosed preclinical inhibitors of amyloid-induced toxicity and neuroinflammation to treat Alzheimer's disease and other amy...